News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,797 Results
Type
Article (39943)
Company Profile (271)
Press Release (658583)
Section
Business (205072)
Career Advice (2020)
Deals (35532)
Drug Delivery (96)
Drug Development (81234)
Employer Resources (172)
FDA (16189)
Job Trends (14900)
News (346410)
Policy (32617)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2564)
Accelerated approval (2)
Adcomms (20)
Allergies (80)
Alliances (49733)
ALS (82)
Alzheimer's disease (1352)
Antibody-drug conjugate (ADC) (110)
Approvals (16188)
Artificial intelligence (225)
Autoimmune disease (14)
Automation (14)
Bankruptcy (362)
Best Places to Work (11658)
BIOSECURE Act (19)
Biosimilars (101)
Biotechnology (190)
Bladder cancer (57)
Brain cancer (24)
Breast cancer (246)
Cancer (1962)
Cardiovascular disease (147)
Career advice (1685)
Career pathing (29)
CAR-T (140)
Cell therapy (394)
Cervical cancer (17)
Clinical research (65801)
Collaboration (764)
Compensation (446)
Complete response letters (18)
COVID-19 (2596)
CRISPR (35)
C-suite (204)
Cystic fibrosis (98)
Data (1897)
Decentralized trials (2)
Denatured (18)
Depression (36)
Diabetes (242)
Diagnostics (6347)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (109)
Drug pricing (97)
Drug shortages (25)
Duchenne muscular dystrophy (84)
Earnings (86258)
Editorial (32)
Employer branding (21)
Employer resources (146)
Events (112087)
Executive appointments (631)
FDA (17276)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (686)
Gene editing (96)
Generative AI (18)
Gene therapy (270)
GLP-1 (681)
Government (4391)
Grass and pollen (4)
Guidances (48)
Healthcare (18824)
Huntington's disease (23)
IgA nephropathy (21)
Immunology and inflammation (108)
Indications (26)
Infectious disease (2725)
Inflammatory bowel disease (135)
Inflation Reduction Act (10)
Influenza (46)
Intellectual property (83)
Interviews (311)
IPO (16517)
IRA (42)
Job creations (3665)
Job search strategy (1434)
Kidney cancer (9)
Labor market (34)
Layoffs (454)
Leadership (15)
Legal (7936)
Liver cancer (70)
Lung cancer (287)
Lymphoma (129)
Machine learning (2)
Management (58)
Manufacturing (265)
MASH (59)
Medical device (13323)
Medtech (13328)
Mergers & acquisitions (19477)
Metabolic disorders (621)
Multiple sclerosis (68)
NASH (16)
Neurodegenerative disease (80)
Neuropsychiatric disorders (24)
Neuroscience (1819)
NextGen: Class of 2025 (6548)
Non-profit (4488)
Northern California (2388)
Now hiring (37)
Obesity (336)
Opinion (205)
Ovarian cancer (71)
Pain (76)
Pancreatic cancer (77)
Parkinson's disease (131)
Partnered (18)
Patents (199)
Patient recruitment (93)
Peanut (46)
People (57390)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (20507)
Phase II (28982)
Phase III (21586)
Pipeline (959)
Podcasts (48)
Policy (111)
Postmarket research (2571)
Preclinical (8682)
Press Release (64)
Prostate cancer (91)
Psychedelics (30)
Radiopharmaceuticals (243)
Rare diseases (351)
Real estate (5947)
Recruiting (65)
Regulatory (22189)
Reports (46)
Research institute (2323)
Resumes & cover letters (350)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (61)
Series A (122)
Series B (77)
Service/supplier (13)
Sickle cell disease (49)
Southern California (2068)
Special edition (14)
Spinal muscular atrophy (148)
Sponsored (28)
Startups (3626)
State (2)
Stomach cancer (12)
Supply chain (59)
The Weekly (27)
United States (20895)
Vaccines (654)
Venture capitalists (38)
Webinars (12)
Weight loss (225)
Women's health (33)
Worklife (15)
Date
Today (26)
Last 7 days (565)
Last 30 days (2614)
Last 365 days (33619)
2025 (7652)
2024 (35339)
2023 (40182)
2022 (51290)
2021 (55836)
2020 (54160)
2019 (46645)
2018 (35128)
2017 (32225)
2016 (31632)
2015 (37716)
2014 (31458)
2013 (26511)
2012 (28777)
2011 (29436)
2010 (27531)
Location
Africa (720)
Alabama (49)
Alaska (7)
Arizona (223)
Arkansas (13)
Asia (37903)
Australia (6208)
California (5458)
Canada (1854)
China (466)
Colorado (245)
Connecticut (256)
Delaware (123)
Europe (81412)
Florida (809)
Georgia (190)
Idaho (58)
Illinois (491)
India (24)
Indiana (290)
Iowa (9)
Japan (138)
Kansas (101)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (823)
Massachusetts (4100)
Michigan (208)
Minnesota (366)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (63)
New Jersey (1548)
New Mexico (28)
New York (1561)
North Carolina (909)
North Dakota (7)
Northern California (2388)
Ohio (192)
Oklahoma (14)
Oregon (34)
Pennsylvania (1239)
Puerto Rico (9)
Rhode Island (26)
South America (1097)
South Carolina (18)
South Dakota (1)
Southern California (2068)
Tennessee (92)
Texas (814)
Utah (163)
Virginia (128)
Washington D.C. (58)
Washington State (507)
West Virginia (3)
Wisconsin (48)
698,797 Results for "ucb biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eye Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB are planning a second late-stage trial by the end of the year to support a drug application.
November 19, 2024
·
3 min read
·
Tristan Manalac
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
UCB Offloads Neurology, Allergy Portfolio in China for $680M
Belgium-based biopharma UCB is selling its Chinese neurology and allergy business to Singapore asset management firm CBC Group and Abu Dhabi investment company Mubadala.
August 26, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
March 19, 2025
·
6 min read
Press Releases
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
March 13, 2025
·
1 min read
Press Releases
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
January 16, 2025
·
14 min read
Press Releases
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
March 10, 2025
·
2 min read
Press Releases
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
February 24, 2025
·
4 min read
Drug Development
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
UCB today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX.
May 23, 2024
·
14 min read
Press Releases
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
February 18, 2025
·
4 min read
1 of 69,880
Next
